Recon Strategy

Biotech analysts studied 229 preclinical asset deals signed between '10–'15 to see which ones reached late stage clinical development & resulted in revenue for licensors h/t @ReconStrategy. Assets without a specified target rarely progressed into the clinic which suggests these programs have l"ow priority or weak preclinical data," they said

In listening to @AcquiredFM on Epic, struck by how well this @TheAtlantic piece I wrote w @ReconStrategy's Tory Wolff & back in 2012(!) -> crossposted @aei: aei.org/articles/is-on… @djrosent @gilbert Anticipates many key themes nicely covered by pcast: acquired.fm/episodes/epic-…

@DShaywitz @matthewherper @TheAtlantic You guys sure called it early!

@matthewherper - in addition to the piece on Epic that Tory Wolff @ReconStrategy & I wrote for the @TheAtlantic in 2012, we also wrote a piece for you that presaged the current conflict: forbes.com/sites/davidsha…

Join us for the last of our Innovate Kidney webinar series hosted by @ReconStrategy on June 5th at 4pm ET! You will learn how to effectively commercialize your product in the midst of growing demand and rising market trends. Register today! us06web.zoom.us/webinar/regist…

Pain may have been the graveyard of drug discovery but now we have found the holy grail. @VertexPharma gets the award for the most exciting mixed metaphor at the @statnews summit. #pain #biotech

Location analysis of Amazon's One Medical (primary care) acquisition by @ReconStrategy. About 2/3 of ONEM's commercial clinics are within 1 mile of a Whole Foods store. "clinics are in 13 of Amazon Care's 23 markets of interest for 2022." h/t @bnikhil reconstrategy.com/2022/07/whats-…

So where's AI in healthcare going next. One window into this is analysis of clinical trial data which capture some dramatic shifts reconstrategy.com/2022/06/advanc…

Every two weeks, I compile the articles and industry updates I think are most worthy of your time into an unconventional newsletter format (below) and send them out via email. But inboxes can be shifty places. By @AnnaRoseWelch cellandgene.com/doc/arw-s-c-g-…

The amazing "Disruptive Dozen" gene and cell therapies at #WMIF2022 will transform care. #7 restores the "brain of the gut." Truly transformative stuff #WMIF2022 @MGBInnovation. @US_FDA good to hear that you're looking for new ways to get these to more patients faster.

Thank you to our sponsors @BankofAmerica @NovartisUS @AstellasUS @BayerUS @ReconStrategy @_CellandGene for helping to make #WMIF2022 possible! worldmedicalinnovation.org/sponsors/?cid=…

We need to decouple technology platforms from product development in gene and cell therapy so every biotech is not trying to reinvent the wheel @rsinghvi from @resilience at #WMIF2022

Genomic sequencing of all babies is critical as progressive degenerative diseases have a narrow window for therapeutic interventions. Diagnosing after symptoms is too late. #WMIF2022 @RobertCGreen @adamjshay @MGBInnovation

Thoughtful and constructive ideas from @ReconStrategy about how to enable repurposing of off-patent molecules. IMHO, legal and regulatory change to enable an ownership option is the most effective course.

Opinion: An effort to develop policies and incentives that support innovation with generics is worth pursuing to leverage the treasure trove of drugs that have been developed over the past decades. buff.ly/3roVxuh

Is this going to be the decade when genomic testing becomes ubiquitous? Investment level is mind boggling and like the heyday of early biotech. @ReconStrategy's Sarah Dolman, has a great piece on picking the winners "The Road Ahead for Genomic Testing" recon.blog/road-ahead-for…

1) Continue to prioritize employees’ wellbeing 2) Be adaptive 3) Step up your comms big time 4) Rethink your biases at work 5) Learn from “Zoom natives” 6) Don’t rush to declare the future Solid advice from @bnikhil @ReconStrategy & Deborah Lovich @BCG hbr.org/2021/08/has-th…

Thank you to our World Medical Innovation Forum Collaborators @Amplify_Bio @bostonsci @CanonUSA @CatalentPharma @InterSystems @nlvcofficial @onemedical @ReconStrategy @SiemensHealth @thermofisher @VertexPharma #WMIF2021

3. Responding to lack of testing infrastructure, @CICcambridge member Nikhil Bhojwani of @ReconStrategy collaborated with Dr. Atul Gawande on a blueprint for scaling COVID-19 testing in the U.S., coining "assurance testing" as a key step towards reopening. cic.com/blogpost/2021/…

Cell and gene therapies aim to cure rare diseases and oncology AND they also address major chronic conditions including #diabetes. Insights from #WMIF2021 @ReconStrategy, @MGBInnovation worldmedicalinnovation.org/white-paper/

Businesses and universities need frequent Covid-19 testing to resume in-person interaction. Online marketplaces for “assurance testing,” as @bnikhil and @Atul_Gawande call it in @HarvardBiz make it simpler and cheaper to test at scale hbr.org/2020/07/a-bett…